Suprachoroidal CLS-TA With Intravitreal Aflibercept Versus Aflibercept Alone in Subject With Diabetic Macular Edema
Part of paid clinical trials in Phoenix, Arizona.
- Sponsor
- Clearside Biomedical, Inc.
- Study ID
- NCT03126786
- Phase
- PHASE2
- Status
- Completed
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- IVT aflibercept — DRUGIVT aflibercept \[2 mg/0.05 mL\]
- Sham SC — DRUGsham SC
- SC CLS-TA — DRUGCLS-TA \[4 mg/100 μL\] SC injection
Study Details
The purpose of this trial is to evaluate the safety and efficacy of suprachoroidal CLS-TA used with intravitreal aflibercept in subjects with DME.
Key Dates
- Start date
- Jul 11, 2017
- Status verified
- Apr 2021
- Primary completion
- Apr 17, 2018
- Completion
- Apr 17, 2018
Study Design
- Enrollment
- 71 participants (actual)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Active Comparator: ActiveTreatment will consist of IVT injection of Aflibercept followed by an SC injection of CLS-TA
- Sham Comparator: ControlTreatment will consist of IVT aflibercept injection followed by a sham SC procedure
Primary Outcome Measure
Mean Change From Baseline in Best Corrected Visual Acuity Letter Score [ Time Frame: Baseline, 6 months ]
Locations (29)
Find similar trials in Phoenix, AZ
By condition
By specialty
By research site
Retinal Consultants of Arizona and Retinal Research Institute· Phoenix, AZRetina Centers, PC· Tucson, AZCalifornia Retina Consultants· Bakersfield, CARetina Vitreous Medical Group Clinical Research· Beverly Hills, CANorthern California Retina Vitreous Associates Medical Group, Inc.· Mountain View, CARetina Institute of California· Palm Desert, CA
Related Studies
- Phase I Study to Assess the Safety and Efficacy of OCU200 for Center-Involved Diabetic Macular Edema (DME)PHASE1 · Recruiting · Ocugen · Deerfield Beach, Florida
- EC-104 Intravitreal Implant for the Treatment of Diabetic Macular EdemaPHASE1/PHASE2 · Recruiting · Eclipse Life Sciences, Inc. · Tampa, Florida
- A Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of RO7823653 in Participants With Diabetic Macular Edema (DME)PHASE1 · Recruiting · Genentech, Inc. · Peoria, Arizona
- CAPRI: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DMEPHASE3 · Recruiting · EyePoint Pharmaceuticals, Inc. · Gilbert, Arizona